BA
LPCN icon

BlackRock Advisors’s Lipocine LPCN Stock Holding History

BlackRock Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$37K Hold
597
– – ﹤0.01% 3323
2016
Q3 		$45K Buy
597
+219
+58% +$13.6K ﹤0.01% 3280
2016
Q2 		$20K Buy
378
+278
+278% +$43.1K ﹤0.01% 3446
2016
Q1 		$17K Hold
100
– – ﹤0.01% 3465
2015
Q4 		$22K Buy
+100
New +$21K ﹤0.01% 3468

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Advisors's LPCN Position: Q4 2016 in Review

BlackRock Advisors held its Lipocine (LPCN) position steady in Q4 2016 at 597 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #3323.

BlackRock Advisors first reported a position in LPCN in Q4 2015 and has held it in 5 quarters since. The position peaked at $45K in Q3 2016. 58 funds tracked by Wall St. Rank hold LPCN as of Q4 2016.

  • BlackRock Advisors held 597 shares of Lipocine worth $37K as of Q4 2016.
  • BlackRock Advisors left its Lipocine share count unchanged in Q4 2016.
  • Lipocine made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3323 holding.
  • BlackRock Advisors first reported a position in Lipocine in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Advisors's Lipocine position peaked at $45K in Q3 2016.
  • 58 funds tracked by Wall St. Rank held Lipocine as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.